NFL makes multiyear commitment to playing regular season games in Melbourne; partners with the Victorian State Government and ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

Shares of Novavax Inc. NVAX slipped 1.69% to $8.13 Friday, on what proved to be an all-around poor trading session for the ...

The stock's fall snapped a two-day winning streak.

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Novavax shares are trading lower by 9.8% during Monday's session. Shares of vaccine stocks are trading lower after Moderna issued 2025 revenue guidance below analyst estimates. Next: Access Our ...

Novavax (NVAX) ended the recent trading session at $8.55, demonstrating a +0.53% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily gain of 1.83% ...

I have been warning about Novavax's risks since 2016, highlighting its ongoing struggles with the FDA. Novavax's Q3 2024 earnings call and 10-Q reveal a collaboration negotiated from a position of ...

In the most recent trading session, Novavax (NVAX) closed at $8.45, indicating a +0.24% shift from the previous trading day. Health and pharmaceutical stocks — including Moderna (MRNA), Pfizer ...